Related Experiment Video
Updated: Jul 13, 2026
10:44
Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System
Published on: May 24, 2017
Varenicline: progress in smoking cessation treatment
Elbert D Glover1, Jessica M Rath
1University of Maryland College Park School of Public Health, Department of Public & Community Health, College Park, MD 20742, USA. eglover1@umd.edu
Expert Opinion on Pharmacotherapy
|August 10, 2007
Summary
Varenicline, a new smoking cessation aid, helps reduce cravings and satisfaction from smoking. Clinical trials show it is effective and well-tolerated for treating tobacco dependence.
Area of Science:
- Pharmacology
- Addiction Medicine
- Neuroscience
Background:
- Varenicline represents a significant advancement in pharmacotherapy for smoking cessation.
- It is the first new smoking cessation aid approved in nearly a decade.
- Tobacco dependence remains a major public health concern globally.
Purpose of the Study:
- To review the mechanism of action, efficacy, and safety of varenicline.
- To highlight varenicline's role in the treatment of tobacco dependence.
- To provide an overview of varenicline as a smoking cessation aid.
Main Methods:
- Review of clinical trial data comparing varenicline to placebo and bupropion.
- Analysis of varenicline's pharmacological profile as a nicotinic acetylcholine receptor partial agonist.
- Assessment of varenicline's safety and tolerability profile.
Main Results:
- Varenicline demonstrated effectiveness in smoking cessation compared to placebo and sustained-release bupropion.
- The drug acts as a partial agonist at alpha4beta2 nicotinic acetylcholine receptors.
- It alleviates nicotine withdrawal symptoms and reduces smoking satisfaction.
- Varenicline exhibits an acceptable safety profile and is well tolerated.
Conclusions:
- Varenicline is an effective and well-tolerated pharmacological aid for smoking cessation.
- Its dual mechanism of action offers a novel approach to treating nicotine dependence.
- Varenicline represents significant progress in the management of tobacco dependence.
Related Concept Videos
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:29Stimulants
Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation